Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences reported a successful End-of-Phase 2 meeting with the FDA for once-weekly canvuparatide, clearing the way to start a Phase 3 trial in chronic hypoparathyroidism in Q3 2026. The double-blind, placebo-controlled study will enroll about 160 patients, randomizing them 3:1 to canvuparatide or placebo, with fixed-dose, titration and maintenance periods and a primary efficacy assessment at week 26.
The trial will track how many patients reach normal blood calcium while no longer needing conventional therapy, along with urinary calcium and other secondary measures, followed by an open-label extension. MBX also highlighted that canvuparatide has orphan drug designation from both the FDA and the European Medicines Agency for chronic hypoparathyroidism, supporting its continued development in the U.S. and Europe.
MBX Biosciences reported a successful End-of-Phase 2 meeting with the FDA for once-weekly canvuparatide, clearing the way to start a Phase 3 trial in chronic hypoparathyroidism in Q3 2026. The double-blind, placebo-controlled study will enroll about 160 patients, randomizing them 3:1 to canvuparatide or placebo, with fixed-dose, titration and maintenance periods and a primary efficacy assessment at week 26.
The trial will track how many patients reach normal blood calcium while no longer needing conventional therapy, along with urinary calcium and other secondary measures, followed by an open-label extension. MBX also highlighted that canvuparatide has orphan drug designation from both the FDA and the European Medicines Agency for chronic hypoparathyroidism, supporting its continued development in the U.S. and Europe.
MBX Biosciences, Inc. director and President & CEO P. Kent Hawryluk reported exercising stock options into common stock. On February 26, 2026, he exercised options covering 28,768 shares, with the resulting common stock recorded at $16.00 per share.
After these transactions, his directly held common stock position is 728,274 shares, and directly held stock options total 91,668 shares underlying options. An additional 468,277 common shares are held indirectly by the P. Kent Hawryluk Revocable Trust, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
MBX Biosciences signed a lease for about 13,642 square feet of new office and lab space in Burlington, Massachusetts. The four-year lease is expected to start around May 1, 2026, with base rent of roughly $68,200 for the first twelve months and aggregate base rent of about $3.4 million, plus operating costs, taxes and utilities.
The company’s Chief Financial Officer, Richard Bartram, will resign effective March 15, 2026, then serve as a consultant to support the transition. He will receive severance under his employment agreement, extended option exercise rights, and a $13,400 lump sum related to COBRA premiums. John Smither, an experienced biotechnology finance executive, has been appointed Interim CFO with a part-time employment agreement that includes a $325,000 base salary, a target bonus equal to 40% of earned income, and a $25,000 sign-on bonus.
MBX Biosciences’ shareholder OrbiMed has updated its ownership position after recent share sales and dilution. OrbiMed Advisors LLC and affiliated funds now report beneficial ownership of 3,637,887 MBX common shares, representing 7.7% of the class based on 47,153,288 shares outstanding.
OrbiMed Capital GP VII LLC is general partner of OrbiMed Private Investments VII, LP, which holds 2,958,000 shares, or 6.3% of outstanding shares. OrbiMed Genesis GP LLC is general partner of OrbiMed Genesis Master Fund, L.P., which holds 679,887 shares, or 1.4% of outstanding shares.
The amendment notes OrbiMed’s percentage ownership fell by more than 1% due to an increase in MBX shares outstanding and reports multiple open-market sales by the Genesis and OPI VII funds in late 2025 and early 2026 at prices between $31.03 and $42.09 per share.
MBX Biosciences received an amended Schedule 13G/A reporting a significant institutional holding by Wellington-affiliated entities. Wellington Management Group LLP and related entities report beneficial ownership of 3,349,961 shares of MBX Biosciences common stock, representing 7.46% of the class as of 12/31/2025.
The shares are held of record by clients of Wellington investment advisers, which share voting and dispositive power over the securities. No single client is known to hold more than five percent of the class. Wellington certifies the position is held in the ordinary course of business and not to change or influence control.
MBX Biosciences, Inc. closed an at-the-market stock sale, issuing 2,250,986 shares of common stock at a volume weighted average price of $38.76 per share for gross proceeds of approximately $87.1 million. The shares were sold through Jefferies under an existing Open Market Sale Agreement and shelf registration on Form S-3.
The company currently plans to use the net proceeds to fund clinical-stage programs, discovery research and development, additional clinical development, and general corporate purposes including working capital and capital expenditures. MBX Biosciences may also use some proceeds and existing cash to in-license, acquire, or invest in complementary businesses or technologies, and still has capacity to sell up to an additional $62.9 million of common stock under the same program.
MBX Biosciences Chief Medical Officer Azoulay Salomon reported new equity compensation. On February 2, 2026, Salomon received 15,000 shares of common stock, representing a grant of restricted stock units that vest over four years in equal quarterly installments, conditioned on continued service.
On the same date, Salomon was also granted a stock option for 70,000 shares of common stock with an exercise price of $39.07 per share. These options vest and become exercisable in 48 equal monthly installments beginning on March 2, 2026, also subject to continued service. Following these grants, Salomon beneficially owns 15,000 common shares and 70,000 derivative securities directly.
MBX Biosciences, Inc.’s Chief Financial Officer Richard Bartram received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 15,000 shares of common stock as RSUs at a price of $0 per share, all held directly after the grant.
He was also granted a stock option to buy 70,000 shares of common stock with an exercise price of $39.07 per share. These options vest and become exercisable in 48 equal monthly installments beginning on March 2, 2026, while the 15,000 RSUs vest in equal quarterly installments over four years. All vesting is conditioned on his continued service with the company.
MBX Biosciences President & CEO P. Kent Hawryluk reported new equity awards. On February 2, 2026, he received 35,250 shares of common stock in the form of restricted stock units at $0 per share, bringing his directly held common stock to 699,506 shares.
He was also granted a stock option to buy 164,500 shares of common stock at an exercise price of $39.07 per share, expiring on February 2, 2036, vesting in 48 equal monthly installments starting March 2, 2026. In addition, 468,277 shares are held indirectly by the P. Kent Hawryluk Revocable Trust, for which he serves as trustee.
MBX Biosciences granted director Laurie Stelzer stock options covering 32,000 shares of common stock on January 20, 2026. These options have an exercise price of $43.14 per share and are held as a direct ownership position.
One-third of the underlying shares will vest and become exercisable on January 20, 2027, the first anniversary of the grant date, with the remaining two-thirds vesting monthly over the following two years, subject to her continued service. After this grant, she beneficially owns 32,000 derivative securities linked to MBX Biosciences common stock.